Before it undertakes a good manufacturing inspection, the UK Medicines and Healthcare Products Regulatory Agency is now asking drug manufacturers to declare whether they have a policy on data integrity/governance. The manufacturer's response on this front, besides other issues, will help the MHRA decide on how frequently the site should be inspected.
Information on a company's data integrity policy is being sought through a revised form – the pre-inspection planning report1 –...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?